title: Correlation between potentiation of neurogenic twitch contraction and benzomorphan sigma receptor binding potency in the mouse vas deferens.
abstract: The effects of sigma receptor ligands on the neurogenic twitch contraction in the ddY mouse vas deferens were studied. In functional studies, (+)-N-allylnormetazocine ((+)-SKF-10,047) and (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)-3-PPP) potentiated neurogenic twitch contractions in a concentration-dependent manner. The potentiation by each (+) enantiomer was significantly more potent than that by the respective (-) enantiomer. In addition, haloperidol and (+/-)-pentazocine also potentiated neurogenic twitch contractions. The order of potentiating ability was: haloperidol > (+/-)-pentazocine > (+)-3-PPP > (-)-3-PPP > (+)-SKF-10,047 > (-)-SKF-10,047. In contrast, other sigma receptor ligands, 1,3-di(2-tolyl)guanidine (DTG) and rimcazole, suppressed this twitch contraction. In addition, rimcazole significantly antagonized the (+)-SKF-10,047-induced potentiation at concentrations which did not affect contractions per se. Furthermore, binding studies showed that the kinetic parameters and the inhibitory potencies of sigma receptor ligands for the binding of [3H](+)-SKF-10,047 in the mouse vas deferens were similar to those in the guinea pig brain. The order of potency of sigma receptor ligands to potentiate the neurogenic twitch contraction in the mouse vas deferens was significantly correlated with the potency to inhibit [3H](+)-SKF-10,047 binding in both mouse vas deferens and guinea pig brain. These results indicate that sigma receptor ligands regulate the neurogenic twitch contraction, which is mediated by rimcazole-sensitive benzomorphan-type sigma receptors.
authors.affiliation: Central Research Laboratories, Santen Pharmaceutical Co., Ltd., Osaka, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Matsuno
authors.forename: T
authors.initials: T
authors.lastname: Senda
authors.forename: S
authors.initials: S
authors.lastname: Mita
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D004357:Drug Synergism; D006168:Guinea Pigs; D006220:Haloperidol / Q000494:pharmacology; D008024:Ligands; D008297:Male; D051379:Mice; D010620:Phenazocine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D017480:Receptors, sigma / Q000187:drug effects / Q000378:metabolism*; D013035:Spasm / Q000139:chemically induced*; D014649:Vas Deferens / Q000187:drug effects* / Q000378:metabolism
chemical_list: D000978:Antiparkinson Agents; D008024:Ligands; D010880:Piperidines; D017480:Receptors, sigma; C012134:SK&F 10047; C026539:preclamol; D010620:Phenazocine; D006220:Haloperidol